Skip to main content
SpringerLink
Log in

Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

In addition to their high-intensity effects on the reduction in low-density lipoprotein (LDL) levels, rosuvastatin and atorvastatin would be expected to also reduce small dense LDL (sdLDL) levels. To determine which reduces sdLDL levels more, we performed the first meta-analysis and meta-regression of randomized head-to-head trials of rosuvastatin versus atorvastatin therapy. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched through April 2012. Eligible studies were prospective, randomized controlled trials of rosuvastatin versus atorvastatin therapy reporting final sdLDL (directly measured or calculated) levels as an outcome. For each study, data regarding final sdLDL levels in both the rosuvastatin and atorvastatin groups were used to generate mean differences (MD) and 95 % confidence intervals (CI). Meta-regression analysis was performed to determine whether the effects of rosuvastatin therapy were modulated by the prespecified factors. Of 159 potentially relevant articles screened initially, 28 reports of randomized trials enrolling a total of 7802 patients were included. Pooled analysis suggested a significant reduction in final sdLDL levels among patients randomized to rosuvastatin versus atorvastatin therapy (MD, −1.56 mg/dl; 95 % CI, −2.30 to −0.83 mg/dl; P < 0.0001). The meta-regression coefficients were statistically significant for the baseline LDL/sdLDL level and the difference in LDL changes between the two groups. In conclusion, rosuvastatin rather than atorvastatin therapy is likely more effective in reduction of sdLDL levels. It should be further investigated whether the reduction in sdLDL levels implies overt clinical benefits of rosuvastatin over atorvastatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Krauss RM, Blanche PJ (1992) Detection and quantitation of LDL subfractions. Curr Opin Lipidol 3:377–383

    Article  CAS  Google Scholar 

  2. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP (2007) Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 7:53–72

    Article  CAS  PubMed  Google Scholar 

  3. Packard CJ (2006) Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol 17:412–417

    Article  CAS  PubMed  Google Scholar 

  4. St-Pierre AC, Cantin B, Dagenais GR, Mauriège P, Bernard PM, Després JP, Lamarche B (2005) Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol 25:553–559

    Article  CAS  PubMed  Google Scholar 

  5. Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, D’Agostino RB, Vasan RS, Robins SJ (2006) Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113:20–29

    Article  CAS  PubMed  Google Scholar 

  6. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM (1996) Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 94:2146–2153

    Article  CAS  PubMed  Google Scholar 

  7. Zambon A, Hokanson JE, Brown BG, Brunzell JD (1999) Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 99:1959–1964

    Article  CAS  PubMed  Google Scholar 

  8. Rosenson RS, Otvos JD, Freedman DS (2002) Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 90:89–94

    Article  CAS  PubMed  Google Scholar 

  9. Rizzo M, Berneis K (2007) Who needs to care about small, dense low-density lipoproteins? Int J Clin Pract 61:1949–1956

    Article  CAS  PubMed  Google Scholar 

  10. Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J (1990) Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 83:59–67

    Article  CAS  PubMed  Google Scholar 

  11. Alabakovska SB, Todorova BB, Labudovic DD, Tosheska KN (2002) Gradient gel electrophoretic separation of LDL and HDL subclasses on BioRad Mini Protean II and size phenotyping in healthy Macedonians. Clin Chim Acta 317:119–123

    Article  CAS  PubMed  Google Scholar 

  12. Hoefner DM, Hodel SD, O’Brien JF, Branum EL, Sun D, Meissner I, McConnell JP (2001) Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 47:266–274

    CAS  PubMed  Google Scholar 

  13. Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, Siscovick D, Freedman DS, Kronmal R (2002) Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 22:1175–1180

    Article  CAS  PubMed  Google Scholar 

  14. Ito Y, Fujimura M, Ohta M, Hirano T (2011) Development of a homogeneous assay for measurement of small dense LDL cholesterol. Clin Chem 57:57–65

    Article  CAS  PubMed  Google Scholar 

  15. Srisawasdi P, Chaloeysup S, Teerajetgul Y, Pocathikorn A, Sukasem C, Vanavanan S, Kroll MH (2011) Estimation of plasma small dense LDL cholesterol from classic lipid measures. Am J Clin Pathol 36:20–29

    Article  Google Scholar 

  16. Ferdinand KC, Clark LT, Watson KE, Neal RC, Brown CD, Kong BW, Barnes BO, Cox WR, Zieve FJ, Isaacsohn J, Ycas J, Sager PT, Gold A, ARIES Study Group (2006) Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol 97:229–235

    Article  CAS  PubMed  Google Scholar 

  17. Deedwania PC, Gupta M, Stein M, Ycas J, Gold A, IRIS Study Group (2007) Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol 99:1538–1543

    Article  CAS  PubMed  Google Scholar 

  18. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896–1900

    Article  CAS  PubMed  Google Scholar 

  19. Higgins JP, Deeks JJ, Altman DG (eds) (2011) Chapter 16: Special topics in statistics. In: Higgins JP, Green S (eds) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration; 2011. http://www.cochrane-handbook.org. Assessed 1 May 2012

  20. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502

    CAS  PubMed  Google Scholar 

  21. Bahadir MA, Oguz A, Uzunlulu M, Bahadir O (2009) Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome. J Atheroscler Thromb 16:684–690

    Article  CAS  PubMed  Google Scholar 

  22. Mori Y, Kuriyama G, Tanaka T, Tajima N (2009) Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes. Endocrine 36:412–418

    Article  CAS  PubMed  Google Scholar 

  23. Ai M, Otokozawa S, Asztalos BF, Nakajima K, Stein E, Jones PH, Schaefer EJ (2008) Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol 101:315–318

    Article  CAS  PubMed  Google Scholar 

  24. Anagnostis P, Selalmatzidou D, Polyzos SA, Panagiotou A, Slavakis A, Panagiotidou A, Athyros VG, Karagiannis A, Mikhailidis DP, Kita M (2011) Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. Int J Clin Pract 65:679–683

    Article  CAS  PubMed  Google Scholar 

  25. Lee CW, Kang SJ, Ahn JM, Song HG, Lee JY, Kim WJ, Park DW, Lee SW, Kim YH, Park SW, Park SJ (2012) Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP Trial). Am J Cardiol 109:1700–1704

    Article  CAS  PubMed  Google Scholar 

  26. Milionis HJ, Rizos E, Kostapanos M, Filippatos TD, Gazi IF, Ganotakis ES, Goudevenos J, Mikhailidis DP, Elisaf MS (2006) Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 22:1123–1131

    Article  CAS  PubMed  Google Scholar 

  27. Brunetti ND, Maulucci G, Casavecchia GP, Distaso C, De Gennaro L, Pellegrino PL, Di Biase M, Brunetti ND, Maulucci G, Casavecchia GP, Distaso C, De Gennaro L, Pellegrino PL, Di Biase M (2007) Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg. J Interv Cardiol 20:481–487

    Article  PubMed  Google Scholar 

  28. Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, Hutchinson H (2002) Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 89:268–275

    Article  CAS  PubMed  Google Scholar 

  29. Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, Sosef F, ECLIPSE Study Investigators (2008) Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology 111:219–228

    Article  CAS  PubMed  Google Scholar 

  30. Her AY, Kim JY, Kang SM, Choi D, Jang Y, Chung N, Manabe I, Lee SH (2010) Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. J Cardiovasc Pharmacol Ther 15:167–174

    Article  CAS  PubMed  Google Scholar 

  31. Hong YJ, Jeong MH, Hachinohe D, Ahmed K, Choi YH, Cho SH, Hwang SH, Ko JS, Lee MG, Park KH, Sim DS, Yoon NS, Yoon HJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC (2011) Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ J 75:398–406

    Article  CAS  PubMed  Google Scholar 

  32. McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P, IN-PRACTICE study (2010) Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. Int J Clin Pract 64:1052–1061

    Article  CAS  PubMed  Google Scholar 

  33. Liu B, Cao HM, Li GY, Liu M, Feng J, Li J, Wang Q (2011) Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endothelial function in patients with atherosclerosis. J Int Med Res 39:2314–2322

    Article  PubMed  Google Scholar 

  34. Mazza F, Stefanutti C, Di Giacomo S, Vivenzio A, Fraone N, Mazzarella B, Bucci A (2008) Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia. Am J Cardiovasc Drugs 8:265–270

    Article  CAS  PubMed  Google Scholar 

  35. Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A, Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group (2004) Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 147:705–713

    Article  CAS  PubMed  Google Scholar 

  36. Okada K, Kimura K, Iwahashi N, Endo T, Himeno H, Fukui K, Kobayashi S, Shimizu M, Iwasawa Y, Morita Y, Wada A, Shigemasa T, Mochida Y, Shimizu T, Sawada R, Uchino K, Umemura S (2011) Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. From the viewpoint of cholesterol metabolism. Circ J 75:2496–2504

    Article  CAS  PubMed  Google Scholar 

  37. Olsson AG, Pears J, McKellar J, Mizan J, Raza A (2001) Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 88:504–508

    Article  CAS  PubMed  Google Scholar 

  38. Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J, Wilpshaar JW, Rosuvastatin Investigators Group (2002) Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 144:1044–1051

    Article  CAS  PubMed  Google Scholar 

  39. Leiter LA, Rosenson RS, Stein E, Reckless JP, Schulte KL, Schleman M, Miller P, Palmer M, Sosef F, POLARIS study investigators (2007) Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 194:e154–e164

    Article  CAS  PubMed  Google Scholar 

  40. Puccetti L, Santilli F, Pasqui AL, Lattanzio S, Liani R, Ciani F, Ferrante E, Ciabattoni G, Scarpini F, Ghezzi A, Auteri A, Davì G (2011) Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 214:122–128

    Article  CAS  PubMed  Google Scholar 

  41. Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH (2005) LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and atorvastatin in different dosages and reverse cholesterol transport) study. Curr Med Res Opin 21:1865–1874

    Article  CAS  PubMed  Google Scholar 

  42. Rawlings R, Nohria A, Liu PY, Donnelly J, Creager MA, Ganz P, Selwyn A, Liao JK (2009) Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in Caucasian men with a previous atherosclerotic event. Am J Cardiol 103:437–441

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE (2011) Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 365:2078–2087

    Article  CAS  PubMed  Google Scholar 

  44. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG (2003) Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 91:33–41

    Article  CAS  PubMed  Google Scholar 

  45. Sindhu S, Singh HK, Salman MT, Fatima J, Verma VK (2011) Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients. J Pharmacol Pharmacother 2:261–265

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Kurabayashi M, Yamazaki T, SUBARU Study Group (2008) Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study-more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy. J Atheroscler Thromb 15:314–323

    Article  CAS  PubMed  Google Scholar 

  47. Tsutamoto T, Sakai H, Ibe K, Yamaji M, Kawahara C, Nakae I, Fujii M, Yamamoto T, Horie M (2011) Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy. Circ J 75:2160–2166

    Article  CAS  PubMed  Google Scholar 

  48. Weng TC, Yang YH, Lin SJ, Tai SH (2010) A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 35:139–151

    Article  CAS  PubMed  Google Scholar 

  49. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ (2010) Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 105:69–76

    Article  CAS  PubMed  Google Scholar 

  50. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ (2010) Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res 51:1546–1553

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, Cupples LA, Wilson PW, Schaefer EJ (2010) Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem 56:967–976

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Koba S, Yokota Y, Hirano T, Ito Y, Ban Y, Tsunoda F, Sato T, Shoji M, Suzuki H, Geshi E, Kobayashi Y, Katagiri T (2008) Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis. J Atheroscler Thromb 15:250–260

    Article  CAS  PubMed  Google Scholar 

  53. Kwon SW, Yoon SJ, Kang TS, Kwon HM, Kim JH, Rhee J, Lee SJ, Park JK, Lim JY, Yoon YW, Hong BK (2006) Significance of small dense low-density lipoprotein as a risk factor for coronary artery disease and acute coronary syndrome. Yonsei Med J 47:405–414

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Rizzo M, Pernice V, Frasheri A, Di Lorenzo G, Rini GB, Spinas GA, Berneis K (2009) Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clin Endocrinol (Oxf) 70:870–875

    Article  CAS  Google Scholar 

  55. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, STELLAR Study Group (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92:152–160

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

No author has any conflict of interest associated with this article.

Author information

Authors and Affiliations

  1. Department of Cardiovascular Surgery, Shizuoka Medical Center, 762-1 Nagasawa, Shimizu-cho, Sunto-gun, Shizuoka, 411-8611, Japan

    Hisato Takagi, Masao Niwa, Yusuke Mizuno, Hirotaka Yamamoto, Shin-nosuke Goto & Takuya Umemoto

Authors
  1. Hisato Takagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masao Niwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yusuke Mizuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hirotaka Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shin-nosuke Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takuya Umemoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hisato Takagi.

Additional information

For the ALICE (All-Literature Investigation of Cardiovascular Evidence) Group.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 836 kb)

Electronic supplementary material: the online version of this article contains supplementary material, which is available to authorized users.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Takagi, H., Niwa, M., Mizuno, Y. et al. Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials. Heart Vessels 29, 287–299 (2014). https://doi.org/10.1007/s00380-013-0358-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-013-0358-6

Keywords

Search

Navigation